StocksMedium•10 November 2026•
1 min read
Ovid Therapeutics Reports $161.4M Cash Position and Funding Runway Through 2029
Key Facts
1Ovid's cash, cash equivalents, and marketable securities totaled $161.4 million as of September 30, 2026.
2The company expects its current financial runway to extend into 2029.
3The company plans to initiate a study in TSC-associated seizures before the end of 2026.
Ovid Therapeutics reported that its cash, cash equivalents, and marketable securities totaled $161.4 million as of September 30, 2026. The company stated in a GlobeNewswire release that it expects its current financial runway to support operations and development programs into 2029. Additionally, the firm plans to initiate a clinical study for TSC-associated seizures before the end of 2026.
OVID closed at $2.85 on November 9, 2026, after trading between a day low of $2.83 and a high of $3.09. The company is currently advancing its KCC2 transporter activators and the OV329 program, with findings from early-stage clinical trials anticipated in 2027 to validate its pipeline for central nervous system disorders.